Category: Parkinson's Disease: Pathophysiology
Objective: To elucidate the oxidized albumin ratio, which is the redox ratio of human non-mercaptalbumin (HNA) to serum albumin (%HNA), as a biomarker in parkinsonism.
Background: Oxidative stress is known as one of the critical factors in the neurodegenerative disorders such as idiopathic Parkinson’s disease (iPD) and related disorders. Therefore, examining oxidative or redox markers might be useful to understand the pathomechanisms of these disorders.
Method: This study was included 216 iPD patients, 15 patients with autosomal recessive familial PD with parkin mutations (PARK2), 30 multiple system atrophy (MSA) patients, 32 progressive nuclear palsy (PSP) patients, and 143 healthy controls (HC). HNA was analyzed using modified high-performance liquid chromatography and uric acid (UA) was also evaluated.
Results: iPD and PARK2 patients showed a higher %HNA than HC (iPD versus HC: 27.7 ± 0.30 versus 23.9 ± 0.38,odds ratio (OR) 1.325, p < 0.001; PARK2 versus HC: 26.2 ± 1.16 versus 23.9 ± 0.38, OR 1.712, p < 0.001). Even iPD patients at an early Hoehn & Yahr stage (I and II) had a higher %HNA than HC. iPD patients showed a higher %HNA than MSA and PSP patients (iPD versus MSA: 27.7 ± 0.30 versus 24.3 ± 0.79, OR 1.249, p < 0.001, iPD versus PSP: 27.7 ± 0.30 versus 25.1 ± 0.81, OR 1.288, p < 0.05). When discriminating iPD patients from HC, %HNA corrected by age was an AUC of 0.750; when discriminating iPD patients from MSA and PSP patients, an AUC of 0.747 was achieved. Furthermore, UA was decreased in iPD patients.
Conclusion: %HNA was significantly increased in iPD and PARK2 patients compared with HC, MSA and PSP, regardless of disease course and severity. UA was also showed similar tendency. Thus, oxidative stress might be increased from the early stages of iPD and PARK2 and play an important role in dopaminergic neuronal degeneration.
To cite this abstract in AMA style:S. Ueno, T. Hatano, A. Okuzumi, S. Saiki, Y. Oji, A. Mori, T. Koinuma, M. Fujimaki, H. Takeshige-Amano, A. Kondo, N. Yoshikawa, T. Nojiri, M. Kurano, K. Yasukawa, Y. Yatomi, H. Ikeda, N. Hattori. Non-mercaptalbumin as a potential biomarker of oxidative stress in Parkinson’s and PARK2 disease [abstract]. Mov Disord. 2020; 35 (suppl 1). https://www.mdsabstracts.org/abstract/non-mercaptalbumin-as-a-potential-biomarker-of-oxidative-stress-in-parkinsons-and-park2-disease/. Accessed December 7, 2023.
« Back to MDS Virtual Congress 2020
MDS Abstracts - https://www.mdsabstracts.org/abstract/non-mercaptalbumin-as-a-potential-biomarker-of-oxidative-stress-in-parkinsons-and-park2-disease/